Legend Biotech Revenue Growth Rates (LEGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Legend Biotech Corporation  (NASDAQ: LEGN)
 

LEGN's Revenue Growth by Quarter and Year

Legend Biotech's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LEGN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 1,028.90
3rd Quarter September 272.33
2nd Quarter June 255.06
1st Quarter March 195.05
FY 1,751.34

LEGNs Annual Revenue
Legend Biotech's Revenue in the fiscal year 2025 $ 1,028.90 millions
Legend Biotech's Revenue in the fiscal year 2024 $ 627.24 millions
Legend Biotech's Revenue in the fiscal year 2023 $ 285.14 millions
Legend Biotech's Revenue in the fiscal year 2022 $ 117.01 millions
Legend Biotech's Revenue in the fiscal year 2021 $ 68.83 millions




LEGN Revenue fourth quarter 2025 Y/Y Growth Comment
Legend Biotech Corporation achieved in the fourth quarter 2025, above Company average Revenue surge of 451.63% year on year, to $ 1,028.90 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Revenue growth. While Legend Biotech Corporation' s Revenue doubling of 451.63% ranks overall at the positon no. 134 in the fourth quarter 2025.


LEGN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 451.63 % -34.59 % 217.56 % 18.64 %
3rd Quarter September 69.98 % - - -
2nd Quarter June 36.75 % - - -
1st Quarter March 107.52 % 158.64 % - -
FY   179.21 % 95.11 % 258.04 % -

Financial Statements
Legend Biotech's fourth quarter 2025 Revenue $ 1,028.90 millions LEGN's Income Statement
Legend Biotech's fourth quarter 2024 Revenue $ 186.52 millions Quarterly LEGN's Income Statement


LEGN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December 277.81 % 16.42 % - -
3rd Quarter September 6.77 % -14.11 % - -
2nd Quarter June 30.77 % 98.45 % - -
1st Quarter March 4.57 % -67.04 % -59.53 % -
FY (Year on Year)   179.21 % 95.11 % 258.04 % -


Back to LEGN Growth rate Comparisons >> Back to LEGN Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #39
Overall #134

Revenue Y/Y Growth Statistics
High Average Low
451.62 % 115.52 % -34.59 %
(Dec 31 2023)   (Dec 31 2021)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #39
Overall #134
Revenue Y/Y Growth Statistics
High Average Low
451.62 % 115.52 % -34.59 %
(Dec 31 2023)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Legend Biotech's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
291.52 % 35.53 % -100 %
(Dec 31 2024)  


LEGN's IV. Quarter Q/Q Revenue Comment
Legend Biotech Corporation achieved in the IV. Quarter 2025 above company average sequential Revenue doubling of 277.81%, to $ 1,028.90 millions, from $272.33 millions in the third quarter.
LEGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Legend Biotech's Revenue growth quarter on quarter, overall rank is 106.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #41
Overall #106
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #41
Overall #106
Revenue Q/Q Growth Statistics
High Average Low
291.52 % 35.53 % -100 %
(Dec 31 2024)  


LEGN's IV. Quarter Q/Q Revenue Comment
Legend Biotech Corporation achieved in the IV. Quarter 2025 above company average sequential Revenue doubling of 277.81%, to $ 1,028.90 millions, from $272.33 millions in the third quarter.
LEGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Legend Biotech's Revenue growth quarter on quarter, overall rank is 106.


Legend Biotech's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 1,028.90 $ 627.24 $ 285.14 $ 117.01 $ 68.83
Y / Y Revenue Growth (TTM) 64.04 % 119.97 % 143.7 % 70 % -8.23 %
Year on Year Revenue Growth Overall Ranking # 174 # 703 # 858 # 0 # 0
Seqeuential Revenue Change (TTM) 64.04 % 119.97 % 143.7 % 70 % -8.23 %
Seq. Revenue Growth (TTM) Overall Ranking # 174 # 703 # 858 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Legend Biotech's cumulative twelve months Revenue were $ 1,029 millions, company would post below average annual Revenue growth of -8.23% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Legend Biotech's Revenue growth from the 272.33% growth in Dec 31 2024.

In the Healthcare sector 46 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 174, from total ranking in previous quarter at 703.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 22
Healthcare Sector # 47
Overall # 174

Revenue TTM Y/Y Growth Statistics
High Average Low
217.56 %
 99.14 %
18.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 47
S&P 500 # 174
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Legend Biotech's cumulative twelve months Revenue were $ 1,029 millions, company would post below average annual Revenue growth of 18.65% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Legend Biotech's Revenue growth from the 272.33% growth in Dec 31 2024.

In the Healthcare sector 46 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 174, from total ranking in previous quarter at 703.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 22
Healthcare Sector # 47
Overall # 174

Revenue TTM Y/Y Growth Statistics
High Average Low
217.56 %
99.14 %
18.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 47
S&P 500 # 174




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LEGN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Abcellera Biologics Inc 788.37%$ 788.374 millions
Xilio Therapeutics Inc 693.85%$ 693.852 millions
Recursion Pharmaceuticals Inc 681.74%$ 681.742 millions
Lightwave Logic Inc 594.54%$ 594.537 millions
Vaxart Inc 586.46%$ 586.460 millions
Abeona Therapeutics Inc 581.04%$ 581.036 millions
Humacyte Inc 558.35%$ 558.354 millions
Nuvation Bio Inc 544.57%$ 544.573 millions
Nexalin Technology Inc 532.46%$ 532.455 millions
Seastar Medical Holding Corp526.87%$ 526.866 millions
Assembly Biosciences Inc 477.26%$ 477.260 millions
Renovorx Inc 453.49%$ 453.488 millions
Legend Biotech Corporation451.62%$ 451.624 millions
Capforce Inc 424.00%$ 424.000 millions
Altimmune inc 420.00%$ 420.000 millions
Vir Biotechnology Inc 417.78%$ 417.779 millions
Cg Oncology Inc 409.21%$ 409.211 millions
Immunitybio inc 406.95%$ 406.952 millions
Aspira Women s Health inc 385.61%$ 385.609 millions
Intercure Ltd 318.38%$ 318.385 millions
Vireo Growth Inc.317.81%$ 317.813 millions
Cormedix Inc 312.10%$ 312.097 millions
Galapagos Nv303.50%$ 303.502 millions
Insmed Inc287.83%$ 287.825 millions
Tscan Therapeutics Inc 286.02%$ 286.015 millions
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions


About Legend Biotech Revenue Growth Rates (LEGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Legend Biotech Corp (CIK 1801198).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001801198-26-000008
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Legend Biotech Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.